Compare Marvell Technology Inc (MRVL) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Neurocrine Biosciences Inc — how do they compare? Marvell Technology Inc trades at $273.56 (market cap $246.84B), while Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B). The key difference: Marvell Technology Inc is far larger — about 17.2× Neurocrine Biosciences Inc's market cap, and Marvell Technology Inc pays a 0.09% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MRVL | NBIX | |
|---|---|---|
Market Cap | $246.84B | $14.36B |
Volume | 29,003,830 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $316.43 | $185.50 |
52-Week Low | $73.73 | $123.10 |
Typical Hold Time | 42 Days | — |
Enterprise Value | $248.19B | $14.37B |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $271.49, down 4.63% today but maintains strong momentum with 210% year-to-date gains. The stock shows bullish technical signals with support at $267 and resistance at $282. Fundamentally, MRVL reported three consecutive earnings beats and projects explosive growth, with fiscal 2028 revenue guidance raised to $18 billion. Analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $327.86 consensus target.
MRVL presents compelling growth prospects driven by AI chip demand and hyperscaler partnerships, particularly the $120 billion Google deal. However, elevated valuation multiples (P/E 90.95, P/S 25.77) and recent net losses (-$885M in 2025) warrant caution. The stock's 210% surge this year increases volatility risk, though strong institutional support and custom silicon expansion provide long-term upside potential.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
